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Internal Medicine, Yale University, School of Medicine, New Haven, CT. 

ABSTRACT 
The outer surface protein (Osp) A of Borrelia burgdorferi, the etiologic 
agent of Lyme disease, is a major protein candidate for a recombinant Lyme 
disease vaccine. We utilized the well-defined murine model of Lyme disease, 
as well as patients with varying stages of disease, to study T cell responses to 
OspA. T cell hybridomas were generated from C3H/HeJ mice immunized 
with recombinant OspA (rOspA) from Borrelia burgdorferi, strain N40. 
Antigenic specificity of the hybridomas was analyzed using rOspA and 
truncated overlapping recombinant glutathione S-transferase (rGST)-OspA 
fusion proteins. Although thirteen T cell hybridomas initially responded 
specifically to rOspA, none reacted with any of the rGST-OspA fragment 
preparations. In the human experiments, we analyzed peripheral blood T cell 
responses of patients with varying stages of Lyme disease to rOspA as well as 
to rOspA digested with cathepsin D, a major lysosomal enzyme responsible 
for degradation of endocytosed proteins for presentation by MHC Class II. 
Purified T cells from three patients, two of whom had high-titer OspA 
antibodies, and all of whom had active disease—both early disseminated and 
late chronic disease—responded specifically to peptide fragments of the 
cathepsin D digest of rOspA. In contrast, no patients with inactive disease 
demonstrated detectable T cell responses. These results suggest that OspA- 
specific T cell responses may be detectable in the peripheral blood of patients 
only during periods of disease activity. 
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INTRODUCTION 
Lyme disease 
Lyme disease is a multi-system disorder caused by infection with the 
tick-borne spirochete Borrelia burgdorferiT Since its first description as an 
epidemic of childhood arthritis in Lyme, CT (from which the disease takes its 
name), the illness has become more widespread (reported most recently in 48 
of 50 states), and the spectrum of clinical manifestations has expanded, now 
including irreversible cardiac, neurologic and rheumatic sequelae. Although 
treatable in its earliest stages, Lyme disease can be difficult to diagnose, and 
later manifestations of the illness may be poorly responsive to antibiotic 
therapy.2'5 
The principal vector for Borrelia burgdorferi in the United States is the 
hard-shelled tick of the Ixodes family.1 The life-cycle of the Ixodes tick spans 
two years, during which time the tick matures through three separate stages: 
larval, nymphal and adult. Ticks feed once per developmental stage, and it is 
generally during its first blood meal that the larva becomes infected with 
Borrelia burgdorferi by feeding on a carrier host. Thus, in regions where the 
preferred host can act as a reservoir for Borrelia burgdorferi (such as white¬ 
footed mice and deer in the northeastern U.S.), prevalence of Borrelia 
burgdorferi infection in ticks ranges from 10 to 50 percent. In contrast, in the 
Pacific coastal regions, Ixodes ticks prefer to feed on lizards which do not carry 
the spirochete, and hence tick infection rates are much lower (1 to 3 percent). 
In the northeastern U.S., infection is most often transmitted to humans by 
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infected nymphs, which typically feed during the summer months, from late 
spring to early fall. 
In humans, the clinical features of Lyme disease progress through 
stages, reflecting localized versus systemic infection.1 Early disease begins 
with the dermal introduction of Borrelia burgdorferi through the bite of an 
infected tick and is localized to the site of the tick bite, where the 
pathognomonic rash erythema migrans (EM) develops. Constitutional 
symptoms marked by fever and generalized malaise as well as 
lymphadenopathy can be seen. After proliferating locally, the spirochete 
disseminates via the bloodstream to other sites (primarily the heart, nervous 
system, and musculoskeletal system), where disease manifestations can be 
seen. As is typical of other borrelial infections, signs and symptoms remit 
spontaneously, even without specific therapy. In some patients, however, 
disease manifestations (primarily arthritis and neurologic disease) become 
chronic, suggesting a role for genetic factors in the expression of disease. The 
response of all stages of illness to antibiotics as well as the finding of viable 
organisms in involved tissues suggest that persistent disease is due to the 
presence of viable spirochetes that have evaded host defenses. 
The increasing incidence, considerable morbidity, occasional 
recalcitrance to therapy, and impracticality of antibiotic prophylaxis have 
made Lyme disease an important public health concern. Recent research has 
focused on elucidating the immunology of Lyme disease with the goal of 
developing an effective recombinant vaccine. 

T Cell Responses to OspA 3 
The human immune response 
The immune response to Lyme disease in naturally infected human 
hosts begins with a nonadaptive component mediated by neutrophils, 
macrophages, and natural killer (NK) cells, followed by an adaptive 
component involving T and B cells.6 The humoral immune response has 
been most extensively studied, and a Borrelia burgdorferi-speciiic antibody 
response is usually detectable in the serum within the first 4 to 6 weeks after 
untreated infection.7*12 The earliest antibodies are directed against the 41 kD 
flagellin protein of Borrelia burgdorferi as well as to higher molecular weight 
heat-shock proteins. Antibodies against the outer surface proteins (Osp) A 
and B, which are diagnostic of immunologic exposure to Borrelia burgdorferi, 
occur late in the course of infection, if at all. Antibiotic therapy early in the 
course of Lyme disease may prevent the development of detectable antibodies 
against Borrelia burgdorferi, although untreated or partially treated patients 
who have recurrent disease manifestations generally are seropositive. In 
addition, although acute and convalescent serum specimens may show 
maturation of the antibody response from IgM to IgG antibodies, new IgM 
responses may occur during exacerbations of disease.8 Despite the presence of 
high-titer Borrelia burgdorferi-specific antibodies, patients with chronic 
disease do not seem to be able to clear their infection, and some researchers 
have implicated the humoral response in the pathogenesis of Lyme 
disease.13'14 Moreover, patients with early disease who are adequately treated 
with antibiotics are not immune to reinfection. 
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The mononuclear cell response to Lyme disease is less understood than 
the humoral response. Early studies documented changes in number and 
responsiveness of various cell types in infected patients, including decreases 
in natural killer cell activity and increases in T suppressor cell activity in the 
early stages, but did not determine whether these changes were specific to 
spirochetal antigens.15'16 More recent studies have demonstrated that at least 
some of these changes are Borrelia burgdorferi-specific.17' 18 Specific 
responsiveness of human peripheral blood mononuclear cells to whole 
Borrelia burgdorferi lysate has been shown, with significantly higher 
responses in synovial or CSF mononuclear cells when patients had 
symptoms referrable to these systems. Most of these mononuclear cell 
responses appear to involve primarily T cells.19 These Borrelia burgdorferi- 
specific responses have been documented in patients even in the absence of 
seropositivity.20 While some have suggested that cellular responsiveness 
should therefore be considered in the diagnosis of Lyme disease, others have 
shown that healthy controls may exhibit similar responses.21 
Relatively little is known about antigen-specific cellular immune 
responses in human Lyme disease. It is likely that T helper cells capable of 
providing B cell help for antibody isotype switching exist and are an 
important component of protective immunity against Borrelia burgdorferi. 
CD4+ T cells have been isolated from the peripheral blood and diseased 
tissues of patients with chronic Lyme disease that react with native and 
recombinant forms of flagellin, heat shock protein 60, and OspA, and with 
recombinant OspA peptide fragments.13' 19' 22-24 However, judging by their 
lymphokine secretion profiles, these T cells appear not to be responsible for 
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providing B cell help, but rather to belong to the CD4+ subset which mediates 
delayed type hypersensivity. CD8+ cells have been isolated from Lyme 
disease patients, but none has demonstrated specificity for borrelial 
antigens.19 
The diversity of T cell populations which may respond to borrelial 
antigens underscores the need to differentiate between epitopes which are 
protective and those which might be pathogenic. To this end, a recent study 
correlated peripheral blood mononuclear cell (PBMC) antigen specificities 
with Lyme disease stage and serology in a number of patients and controls.19 
PBMC responsiveness did not correlate well with serologic status, again 
suggesting that non-antibody promoting T cells play a role in Lyme disease. 
In addition, patients with both early and late disease showed heightened 
cellular responsiveness to whole Borrelia burgdorferi and to recombinant 
OspA compared to controls, but only patients with early disease demonstrated 
increased T cell responsiveness to flagellin compared to controls. The study 
did not investigate the stimulatory effect of OspA or flagellin fragments and 
did not subtype the peripheral blood lymphocytes which were used in the 
assay. Thus, to date, a detailed study which investigates epitope specificities of 
T cell subtypes and correlates these with Lyme disease stage has not been 
reported in the literature. 
The animal model 
The development of a model for Lyme disease in immunocompetent 
mice has permitted more detailed analysis of the normal host response to 
infection with Borrelia burgdorferi. All strains of mice are susceptible to 
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infection, although disease severity appears to vary with age and genotype.25' 
27 The C3H/HeJ mouse has a genetic background making it more susceptible 
to severe disease and therefore is the strain that has been most extensively 
studied. Mice challenged intradermally with Borrelia burgdorferi have viable 
spirochetes in their bloodstream as early as day 3 of infection and 
subsequently develop carditis and arthritis that clinically and histologically 
resembles that seen in human Lyme disease.27 Disease severity peaks around 
day 14 after challenge inoculation, then subsides spontaneously despite 
persistent infection. As in human Lyme disease, recurrent bouts of disease 
activity can be seen. 
Natural immunity 
Mice develop antibodies to a number of Borrelia burgdorferi proteins 
after challenge inoculation, including the 41 kD flagellin, OspA, and OspB 
proteins, although the time course of their appearance is dependent upon the 
number of spirochetes inoculated. Thus, mice inoculated intradermally with 
104 spirochetes develop OspA and OspB antibodies within the first two weeks 
of infection, whereas with lower syringe inocula, Osp antibodies appear much 
later, if at all.28 In this regard, the murine humoral response appears 
identical to that seen in human Lyme disease. 
Murine cellular immune responses to Borrelia burgdorferi infection 
are less well studied than human cellular responses. Several strains of mice 
pre-sensitized with inoculations of live Borrelia burgdorferi have been 
shown to exhibit delayed type hypersensitivity on subsequent intradermal 
exposure to the spirochete, as well as in vitro T cell responsiveness to 
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spirochetal antigens (the latter not seen in naive T cells).29 The strains 
represented several H-2 haplotypes, paralleling the variety of HLA haplotypes 
involved in human T cell responses to Borrelia burgdorferi.13 Another study 
has documented that Borrelia burgdorferi and recombinant OspA and OspB 
induce non-specific proliferation in naive murine splenocytes, primarily in 
the B cell fraction.30 This finding differs from the finding in human 
experiments that T cells predominate in the cellular response. It is similar, 
however, in its demonstration that apparent antigen-specific cellular 
responsiveness may actually be nonspecific, and it emphasizes the need for 
caution in interpreting such assays. To date, the specific epitopes and the 
cellular subtypes involved in these responses remain unknown. 
Protective immunity 
Humoral immune responses are an important arm of host defense 
against Borrelia burgdorferi infection.31' 32 Passive immunization of naive 
mice with immune serum derived from mice infected with Borrelia 
burgdorferi for 90 days confers protection against challenge inoculation with 
108 spirochetes.33-35 Antibodies present in 90-day immune mouse serum 
include those with specificities for flagellin, OspA, and OspB.36 The specific 
antibodies that provide protection have been partially elucidated through 
active immunization studies using Borrelia burgdorferi-specific recombinant 
proteins.35' 37 It is interesting to note that although the predominant 
humoral response in early Lyme disease is directed against the flagellin 
protein, immunization of mice with a recombinant flagellin does not elicit 
neutralizing antibodies. However, active immunization of mice with 
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recombinant OspA or passive administration of OspA antiserum fully 
protects them from Borrelia burgdorferi challenge infection. Similarly, OspB 
antibodies confer some protection, albeit at lower challenge inocula (103), 
indicating that these two outer membrane proteins are important targets of 
host defense.36 
Epitope mapping studies of monoclonal antibodies derived from OspA 
immunized mice demonstrate that protective OspA antibodies bind a 
conformational epitope included within amino acids 133 to 273, the carboxyl 
half of the 273 amino acid protein.38 Using similar methods, protective 
epitopes on OspB have also been localized to the carboxy terminus.39 This 
finding has important implications for vaccine development, in that much of 
the variation of OspA and B sequences among Borrelia burgdorferi strains is 
in the carboxyl half of the protein.40' 41 Indeed, passive immunization of 
naive mice with OspA antisera derived from mice immunized with OspA, 
strain N40, does not protect them from challenge infection with Borrelia 
burgdorferi strain 25015.42 Other immunization studies have documented 
protection across some, but not all, strains, raising concerns over the 
feasibility of designing a universal vaccine. 
Vaccine development 
The ideal recombinant OspA-based Lyme disease vaccine would be 
long-lived, effective for most humans, and protective against most strains of 
Borrelia burgdorferi. As immunologic memory is driven by T cells, 
incorporation of OspA peptide sequences which are shared among strains of 
Borrelia burgdorferi and which preferentially stimulate T helper cells 
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responsible for B cell help is critical to the development of a long-lived 
vaccine. These sequences should also avoid stimulating other T cell 
populations (e.g., suppressor cells, inducer cells) and should be presentable by 
a range of MHC Class II phenotypes.43-48 
Goal of the present study 
The present study was undertaken to define regions of the OspA 
protein that contain T helper cell epitopes capable of promoting protective 
antibody production. A potential outcome of the study would be the 
identification of T helper cell epitopes within regions of the OspA molecule 
with less strain-to-strain variation. In addition, OspA-specific T cell responses 
from patients with various stages and activities of Lyme disease were studied 
to determine when in the course of natural infection such responses can be 
detected. 
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MATERIALS AND METHODS 
Murine Experiments 
Animals 
All murine experiments utilized 6 to 8 week old C3H/HeJ mice 
purchased from The Jackson Laboratory (Bar Harbour, ME). Mice were 
housed in filter cages and given food and water ad libitum. Mice were 
sacrificed by either cervical dislocation or by carbon dioxide asphyxiation. 
Stimuli 
Recombinant OspA 
A soluble recombinant form of OspA, strain N40 (rOspA), was obtained 
from Linda Bockenstedt (Department of Internal Medicine, Yale University). 
This protein differs from the native OspA in that the first 17 amino acids, 
which comprise the leader sequence of the membrane-bound protein, have 
been replaced with a single alanine residue. This modification permits 
expression of a soluble OspA protein in Escherichia coli (E. coli) lysates. 
Briefly, the polymerase chain reaction (PCR) was used to amplify OspA-N40 
genomic DNA, using appropriate oligonucleotide primers with flanking 
restriction sites to facilitate subcloning. Amplified segments were subcloned 
into the vector pET 9c (Novagen, Madison, WI), which utilizes transcription 
and translation signals from bacteriophage T7. E. coli strain DH5oc was 
transformed with the plasmid, and protein expression was induced with 
isopropyl (3-D-thiogalactoside (IPTG). The induced rOspA was purified by ion 
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exchange chromatography as previously described.49 The resultant protein 
was greater than 90 percent pure as determined by SDS-PAGE and reacted on 
immunoblots with anti-N40 antisera. Immunization of mice with the rOspA 
conferred protection against challenge infection (data not shown). 
Glutathione S-transferase 
The plasmid pGEX-2T (Pharmacia Fine Chemicals, Piscataway, NJ) 
contains the gene encoding glutathione S-transferase (GST) under the control 
of the tac promotor. E. coli DH5a were transformed with pGEX-2T, and 
protein expression was induced with IPTG. Induced recombinant GST (rGST) 
was purified to homogeneity by passing E. coli lysate supernatants over 
glutathione sepharose 4B beads (Pharmacia) according to the manufacturer's 
protocol. 
rGST-OspA fusion proteins 
OspA-N40 fragments, recombinantly expressed as fusion partners with 
GST as previously described,38 were obtained from Erol Fikrig (Department of 
Internal Medicine, Yale University). Briefly, OspA gene fragments were 
amplified by PCR using oligonucleotide primers containing restriction 
enzyme recognition sites to facilitate subcloning. Amplified fragments were 
digested with the appropriate restriction enzymes, purified by agarose gel 
electrophoresis, and then subcloned into pGEX-2T in frame with the GST 
gene. Following transformation of E. coli with the plasmid, protein 
expression was induced with IPTG. Induced rGST-OspA proteins contained 
in the cell lysate supernatant were purified using glutathione sepharose 4B 
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columns (Pharmacia). Anti-OspA antisera bound to each rGST-OspA 
fragment on immunoblots.38 Recombinant GST-OspA fragments used in the 
present study were as follows (Figure 1): fragment 1 (OspA amino acids 1-76), 
fragment 2 (OspA amino acids 66-143), fragment 3.4 (OspA amino acids 133- 
273), fragment 550 (OspA amino acids 183-273), fragment 650 (OspA amino 
acids 216-273), and fragment 9 (OspA amino acids 243-273). 
Preparation of murine antigen presenting cells 
Spleens were harvested from normal or rOspA-immunized mice and 
disrupted using glass slides into single cell suspensions in Dulbecco's 
Modified Essential Medium (DMEM) supplemented with 10% heat- 
inactivated fetal calf serum and 1% penicillin/streptomycin/L-glutamine 
(complete DMEM-10). Splenocytes were washed, then incubated for 5 
minutes at room temperature with 5 ml red blood cell lysing buffer (Sigma 
Chemical, St. Louis, MO). After washing twice in complete DMEM-10, cells 
were resuspended at a concentration of 2 x 106 cells/ml and irradiated (2500 
rads) using a cesium source. 
Generation of murine T cell hybridomas 
Murine T cell hybridomas were obtained from Linda Bockenstedt 
(Department of Internal Medicine, Yale University). Mice were immunized 
via footpad and base of tail with 50 |ig rOspA in complete Freund's adjuvant. 
Ten days after immunization, mice were sacrificed, and regional lymph nodes 
were removed and dissected into single cell suspensions. 5 x 106 lymph node 
cells were cultured with 50 pg/ml rOspA for 3 days in complete DMEM-10, 
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then fused with an equal number of BW5147 lymphoma cells using 50% 
polyethylene glycol as described.50' 51 Successful fusions were selected using 
hypoxanthine-aminopterin-thymidine (HAT) medium supplement, and 
individual hybridomas were screened for rOspA specificity by testing their 
ability to produce lymphokines in response to this antigen. A total of 19 
rOspA-specific hybridomas were obtained from two separate immunization 
procedures and used in the present studies. 
Hybridomas were maintained in complete DMEM-10 supplemented 
with hypoxanthine-thymidine (HT) plating medium. At the time of assay, 
the desired number of cells were aliquoted into 15 cc conical tubes, washed 
twice, and resuspended at a concentration of 106 cells/ml in complete DMEM- 
10. 
Stimulation tests 
Interleukin quantification assay 
The murine T cell hybridoma stimulation experiments utilized a 
previously described assay using the IL-2/IL-4-dependent CTLL-2 murine T 
cell line.52' 53 This assay indicates the presence of IL-2 or IL-4 in a test solution 
by determining the viability of CTLL-2 cells (as determined by 3H-thymidine 
incorporation) after 48-hour incubation in the solution relative to control IL- 
2. The CTLL-2 line is dependent upon IL-2 or IL-4 for cell growth and 
therefore can be used as an indicator for the presence of these lymphokines in 
hybridoma supernatants. 
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The CTLL-2 cell line was obtained from Kathy Deponte (Department of 
Internal Medicine, Yale University). Cells were maintained in IL-2 assay 
medium (DMEM supplemented with 10% fetal calf serum, 1% 
penicillin/streptomycin, 1% L-glutamine, and 5 x 10'5 M (3-mercaptoethanol), 
with human recombinant IL-2 (rIL-2, Gibco BRL, Grand Island, NY) added 
weekly to a final concentration of 1 U/ml to sustain growth. Cells were 
collected for interleukin quantification one day prior to their scheduled IL-2 
feedings. 
CTLL-2 cells were washed 3 times in IL-2-free medium, then 
resuspended at 105 cells/ml in IL-2 assay medium. 5 x 103 CTLL-2 cells were 
added to the wells of flat-bottom, 96 well microtiter dishes. In a control 
experiment, these cells were incubated with 50 pi aliquots of rIL-2 at varying 
concentrations, in a total volume of 100 pi for 48 hours at 37° C. In 
subsequent experiments, the cells were incubated with 50 pi of either IL-2 
assay medium, hybridoma supernatant (see below), or 1.3 U/ml rIL-2. 
Initially, 1 pCi 3H thymidine (Tdr, 80 Ci/mmol, DuPont NEN, Boston, MA) 
was added to each well during the last 18 hours of culture, after which cells 
were harvested and counted using a Beckman beta-scintillation counter. 
Later experiments (see figure legends) added 3H-thymidine only during the 
final four hours of culture. 
Screening of hvbridomas for rOspA and rGST-OspA reactivity 
105 hybridoma cells were cultured in triplicate in 200 pi final volume 
with 106 splenocytes and either medium alone or the following experimental 
antigens: rOspA (50 pg/ml), rGST (50 pg/ml), and rGST-OspA fusion 

T Cell Responses to OspA 15 
fragments (10 pg/ml). Recombinant GST and rOspA were used at 10 pg/ml 
final concentration when they served as controls for the rGST-OspA fusion 
fragment stimulation tests. Cultures were incubated for 48 hours at 37° C, 
after which time supernatants (100 X from each well) were collected, 
combined within triplicates, and assayed for the presence of interleukin as 
described above. 
Human Experiments 
Patients 
The patients in this study attended the Yale University Lyme Disease 
Clinic or came from private physician offices in the area (Table 1). All 
patients satisfied the Center for Disease Control (CDC) criteria for Lyme 
disease. Patient D.D. was a healthy volunteer without prior documentation 
of Lyme disease or tick bite, and with negative serologies. 
Patient N.R. had a history of acute disseminated Lyme disease 
manifested by erythema migrans and seronegative lymphocytic meningitis; 
these had resolved with antibiotic therapy, and N.R. had been symptom-free 
for several months at the time of testing. 
Patient A.G. had a history of acute disseminated disease, initially 
presenting with third-degree atrioventricular block. This condition required 
hospitalization and resolved with antibiotics; A.G. was tested shortly before 
discharge from the hospital, at which time elevated IgG responses against 
several Borrelia burgdorferi proteins, including OspA, were present. IgM 
responses were not detected. 
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Patient J.B. also had acute disseminated Lyme disease presenting with 
third-degree atrioventricular block. This condition resolved over two days 
with antibiotics, and J.B. was tested shortly before hospital discharge. Unlike 
patient A.G., J.B. had positive Lyme titers of both IgM and IgG; neither of 
these responses, however, was against OspA or OspB. 
Patient S.A. had a two-year history of Lyme arthritis of the knee which 
had resolved following antibiotic therapy and arthroscopic synovectomy. 
Although IgM antibodies were never detected, S.A. exhibited a high IgG 
response against several Borrelia burgdorferi proteins, including OspA and 
OspB, during active disease. This response had fallen to 1:1600 (with no 
detectable anti-Osp antibodies) at the time of the current study, at which time 
the disease had been inactive for one year. 
Patient A.C. had chronic active Lyme disease manifested primarily by 
persistent arthritis which was clinically active at the time of testing. High IgM 
and IgG Lyme titers detected by ELISA during the period of most active 
disease had fallen somewhat by the time of this study, although IgG responses 
against a number of spirochetal antigens, including OspA, remained 
detectable by Western blot. 
T cell stimulation tests (see below) of patients D.D., N.R., and S.A. were 
performed by Dee Dockery, while tests of A.G., J.B., and A.C. were conducted 
by Kathy Deponte and Nancy Marcantonio (Department of Internal Medicine, 
Yale University). Stella Cretella or Erol Fikrig (Department of Internal 
Medicine, Yale University) provided serologic data. 
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Stimuli 
Phytohemagluttinin 
Phytohemagluttinin (PHA, Burroughs-Wellcome, Research Triangle 
Park, NC) was used as a non-specific mitogen at 1 pg/ml final concentration. 
Recombinant OspA 
Recombinant OspA was prepared as described above. 
OspA cathepsin digests 
Separate fractions of peptide fragments from cathepsin D digestion of 
rOspA were obtained from Kathy Deponte and Nancy Marcantonio 
(Department of Internal Medicine, Yale University). Briefly, 2 mg rOspA (in 
500 pi as a stock solution) was resuspended in an equal volume of 160 mM 
sodium acetate buffer, pH 4.0. 100 jil of cathepsin D stock (Sigma, 5 U/ml) was 
added, and the solution was incubated in a 37° C water bath for 7 hours. 
Another 100 pi of cathepsin D was added to the sample, and it was incubated 
in a 37° C water bath overnight. 200 pi of 2M Tris/HCl was added to the 
sample to terminate the reaction. An equal volume of acetonitrile was then 
added to the sample to precipitate large residues. After cooling to room 
temperature for 4 hours, the sample was centrifuged, and the supernatant was 
collected, lyophilized, and sent to the Yale Protein Chemistry Laboratory (Ken 
Williams) for fractionation over an HPLC column. An automatic peak 
detector identified peptide fragments, and these were collected in fractions at a 
rate of 0.5 ml/minute. 
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Preparation of human antigen presenting cells 
120 ml of blood was obtained from each human volunteer from an 
antecubital vein using aseptic technique. Peripheral blood lymphocytes 
(PBLs) were separated by Ficoll-hypaque centrifugation and washed twice in 
RPMI 1640 medium (RPMI). The cell pellet was resuspended in 5 ml red 
blood cell lysing buffer (Sigma) and incubated at room temperature for 5 
minutes. The resultant purified PBLs were washed twice and resuspended in 
RPMI supplemented with 10% FCS, 1% penicillin/streptomycin and 1% 
glutamine (complete RPMI-10). (Some experiments utilized RPMI 
supplemented with 8% autologous serum in place of 10% fetal calf serum; see 
figure legends.) Half of the PBL's were irradiated (2500 rads, cesium source) 
for use as antigen presenting cells, and T cells were purified from the 
remainder. 
Preparation of human T cells 
PBLs were depleted of adherent cells by plastic adherence for 1 hour at 
37°C. T cells were purified from the nonadherent cell population by passing 
over a nylon wool column as described.54' 55 Typical yields of purified T cells 
from 120 ml of whole blood were 2 x 107 cells. 
Stimulation tests 
40 pi aliquots were collected from each fraction of cathepsin D-digested 
rOspA, and aliquots from sequential fractions were often pooled. The 
resulting solutions were dried in a speed vac and resuspended in 320 pi assay 
medium. 
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5 x 105 T cells were cultured in triplicate in 200 pi final volume with 106 
APCs and 100 pi of cathepsin D-digested rOspA fractions. Control stimuli 
included phytohemagluttinin (PHA, 1 pg/ml), rOspA (50 pg/ml), whole 
cathepsin digest of rOspA, and assay medium alone. After two days in a 
humidified CO2 incubator at 37° C, 1 pCi 3H-thymidine was added to each 
well for four hours. Cells were then harvested from each well using a 
Skatron harvester, and cellular proliferation measured by quantitating 
incorporation of 3H-thymidine into cells with a Beckman beta-scintillation 
counter. 
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RESULTS 
Murine Experiments 
Validity of interleukin quantification assay 
The CTLL-2 assay accurately quantified interleukin levels in control 
solutions (Figure 2). Cells in the system failed to proliferate in medium alone 
and in medium with rOspA (negative controls), but exhibited a characteristic 
proliferative response when exposed to various concentrations of rIL-2: 
positive dose-responsiveness at low to medium interleukin concentrations 
and inhibition at high concentrations. 
Initial screening of murine T cell hybridomas 
In order to determine regions of the OspA protein that contained 
peptides reactive with T cells from C3H/HeJ mice, T cell hybridomas were 
generated from mice immunized with rOspA. Of 13 successful fusions tested 
from one immunization experiment, all showed reactivity to rOspA, whereas 
a control T cell hybridoma specific for the acetyl choline receptor and another 
specific for ovalbumin did not (Figure 3). Supernatants from unstimulated 
hybridomas did not support the growth of CTLL-2 cells, confirming that these 
hybridomas did not spontaneously secrete interleukins nor did they react 
with antigenic components present in fetal calf serum. The rOspA-specific 
hybridomas were subsequently frozen in liquid nitrogen for several months 
until rGST-OspA proteins were available to test their specificities. 
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When retrieved from storage in liquid nitrogen, the rOspA-specific T 
cell hybridomas were again screened using the CTLL-2 assay for reactivity 
with rOspA. Of 12 unstimulated hybridomas tested (data not shown), 
supernatants from three (#1, 3, and 9) stimulated CTLL-2 cell growth, 
suggesting that they responded to antigens in fetal calf serum or 
spontaneously secreted interleukins. Analysis of supernatants from multiple 
hybridoma culture preparations stimulated with either a control antigen 
(rGST) or with rOspA indicated that only one hybridoma (#12) consistently 
responded to rOspA (Figures 4, 5, and 6). Because of the low retrieval rate of 
rOspA-specific T cell hybridomas from storage, a second panel of T cell 
hybridomas was generated from mice immunized with rOspA. Of five 
successful fusions, none showed specificity for rOspA (Figure 7). Thus, only 
hybridoma #12 was selected to undergo stimulation with rGST-OspA 
fragments. 
The overall degree of 3H-thymidine incorporation differed significantly 
among these screening assays. In the assays pictured in Figures 2, 4, and 5, 3H- 
thymidine was added a day before cell harvesting. In the remaining assays, all 
with lower counts, 3H-thymidine was added only four hours before 
harvesting (see figure legends). 
Stimulation of murine T cell hybridoma #12 with rGST-OspA fragments 
Hybridoma #12 was stimulated for 48 hours with either rGST, rOspA 
or the rGST-OspA truncated fragments, after which supernatants were tested 
for the presence of IL-2 and IL-4 (Figure 8). Although previously reactive to 
rOspA, hybridoma #12 failed to react with either rOspA or any of the rGST- 
s 
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OspA fragments when compared to negative controls. Indeed, 3H-thymidine 
incorporation was low in all preparations. Repeating the experiment using 
recently passaged hybridoma cells yielded similar results (data not shown). 
Human Experiments 
Stimulation of human peripheral T lymphocytes with OspA fragments 
The second phase of this study was to evaluate responses of T cells 
from patients with varying stages and activity of Lyme disease to rOspA and 
to rOspA peptide fragments. Recombinant OspA peptide fragments were 
generated by digesting rOspA with cathepsin D, a major lysosomal enzyme 
involved in processing endocytosed antigen for presentation by MHC Class II 
molecules.56 The peptide fragments generated were too numerous to test 
individually and therefore were grouped according to time period collected 
(duration of collection time ~ amount of peptide). Positive responses were 
those which exceeded ten thousand counts per minute and which were more 
than three times greater than responses to medium alone. 
Nylon wool purified T cells (NWTs) from one control subject without 
documented tick bite or Lyme disease responded to the whole digest but to 
none of the fractions (Figure 9); in addition, background responsiveness was 
high compared to other patients. The response to whole digest was surprising 
and may have been due to non-specific mitogens in the preparation or to 
subclinical exposure to Borrelia burgdorferi in the laboratory. T cell 
responsiveness to Borrelia burgdorferi antigens in control populations has 
been seen in other studies as well.21 
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NWTs were isolated from patients with acute disseminated Lyme 
disease during and shortly after disease activity was apparent clinically (N.R., 
A.G., and J.B.). Two patients with chronic disseminated Lyme disease, one of 
whom had significant persistent disease (A.C.) and the other who had not had 
disease activity for over a year (S.A.) were also studied. The patient profiles 
and antibody reactivities are shown in Table 1. NWTs from patient N.R., 
who was tested several months after resolution of Lyme meningitis, failed to 
respond to rOspA or to any OspA fragments (Figure 10). Two patients 
presented with third degree heart block and were tested during their illness or 
within a month thereafter. Patient A.G. had serum antibodies to OspA at the 
time of the study; NWTs showed partial reactivity with rOspA and with 
fraction 48-54 of the digest, and full reactivity with the rOspA digest; the 
response to PHA in this patient was low compared to the other patients 
whose response to PPLA was assayed (Figure 11). Patient J.B. had no detectable 
serum antibodies against OspA, but NWTs from this patient also showed 
reactivity with several rOspA peptide fragments (Figure 12). J.B.'s NWT 
responsiveness was unusual, however, in that T cells responded more to 
medium than to whole OspA digest. 
The responses of NWTs from patients with chronic disseminated 
Lyme disease, both of whom had serum antibodies to OspA, were correlated 
with disease activity in a manner similar to that of patients with early acute 
disseminated disease. NWTs from patient S.A., who had chronic inactive 
Lyme disease and a history of OspA seropositivity, but negative OspA 
serology at the time of this study, responded to the rOspA digest in a pattern 
indistinguishable from that of patient N.R. (Figure 13). However, NWTs 
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from patient A.C., with chronic active Lyme disease and moderate anti-OspA 
titers, clearly responded to one cluster of fractions (16-21) of the rOspA digest 
(Figure 14). Also, like patient J.B., A.C.'s NWT response to intact OspA was 
little different from the response to medium alone. 
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DISCUSSION 
At the present level of understanding, Lyme disease remains both a 
puzzling and debilitating illness. Improved clinical management- 
prevention, diagnosis, therapy, prognosis—requires a firmer understanding of 
its pathogenesis and of the host immune response to infection. A wealth of 
literature has been reported on the B cell responses of mice and humans 
infected with Borrelia burgdorferi, but relatively little is known about cellular 
responses. Recently a recombinant vaccine has been developed using the 
full-length OspA protein from Borrelia burgdorferi. The efficacy and safety of 
this vaccine is as yet unknown. The studies reported herein were undertaken 
with two goals in mind: the first, to determine regions of the OspA protein 
that stimulate T helper cell responses capable of promoting specific antibody 
production; and the second, to determine at what point during natural 
infection T cell responses to OspA can be detected. The murine experiments 
in the present study focused on the former context, while the human 
experiments focused on the latter. 
Murine experiments 
The murine experiments in the present study were designed to 
determine which regions of the OspA protein contain epitopes recognized by 
T cell receptors present in the repertoire of the C3H/HeJ mouse. During the 
course of natural Borrelia burgdorferi infection, it has not been possible to 
demonstrate convincingly that OspA-specific T cells are present in mice.30 
We had hoped that immunization of mice with rOspA using adjuvant would 
allow for the isolation of T cells reactive with rOspA. Although the initial 
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screen of T cell hybridomas suggested that they were OspA-specific, 
subsequent analysis failed to support this conclusion. It is possible that 
cryostorage of the hybridomas, which were not clonal, permitted the growth 
of contaminating nonspecific hybridomas or other cell types upon 
subculturing. The single hybridoma that appeared specific for rOspA 
(hybridoma #12) after cryostorage did not retain this phenotype after 
passaging in culture over time. Although not tested by immunofluorescence 
staining, the most likely reason for loss of specificity is the loss of T cell 
receptor expression on the cell surface, a phenomenon not infrequently 
encountered in long-term culture of hybridomas. A second panel of T cell 
hybridomas generated from rOspA-immunized mice showed no OspA 
specificity, and given the time limitations of the study, generation of 
additional panels was not attempted. 
Human experiments 
The human experiments in the present study were designed to identify 
segments of the OspA protein which stimulate the T cells of patients with 
Lyme disease and to identify correlations between cellular responsiveness and 
clinical parameters such as disease stage, disease activity, and serologic status. 
Although OspA constitutes the majority of the outer surface protein of 
Borrelia burgdorferi, OspA-specific antibodies are usually undetectable in 
early disease. The reasons for this are unknown. One may look to the 
spirochete itself and speculate that OspA expression is down-regulated during 
early infection and subsequently expressed for particular reasons (such as 
invasion of endothelial cells) during the spirochete life span, or that OspA 
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eludes detection by mutation or genetic recombination. Such spirochete- 
oriented models would predict low levels of T cell priming in early disease 
which, during the process of dissemination, increase to levels which can 
provide B cell help. OspA-specific T cell responses might increase shortly 
before the appearance of anti-OspA antibodies and enter a memory cell 
population as the disease activity subsided. 
Alternately, host factors may explain the late seroconversion to OspA. 
OspA and other borrelial antigens may stimulate cell populations which do 
not contribute to, or which even inhibit, anti-OspA antibody production. 
Though their cell sampling method was non-random, Peltz et al. have 
documented preferential activation of Borrelia burgdorferi-specific T helper 
type 1-like cells in seronegative patients with active disease and have 
suggested that this CD4+ subset, unlike T helper type 2 cells which stimulate 
antibody production, may actually play a pathogenic role.23 This model 
would predict low or absent T helper 2 cell priming in early disease, with 
varying levels of T helper 1 priming, possibly correlating with disease activity, 
and increasing responsiveness of both types of CD4+ T cells later in disease. 
OspA-specific T cell responses would appear perhaps long before 
seroconversion and would wax and wane with disease activity. 
The preliminary results of our human experiments are consistent with 
both models of T cell behavior. T cells from controls and from patients with 
both early and late inactive disease (D.D., N.R., S.A.), all of whom were OspA 
seronegative at the time of this study, failed to respond convincingly to OspA 
in its intact or fragmented form. (The control's response to whole digest in 
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the presence of elevated background responsiveness was of questionable 
significance and needs to be reassayed.) In contrast, patients with early and 
late active disease (A.G., J.B., A.C.), two of whom were OspA seropositive, did 
demonstrate T cell responses against intact OspA and against certain fractions 
of the cathepsin D digested protein. (An irregularity in these results involves 
patient J.B.'s greater response to medium alone than to rOspA or to whole 
OspA digest; patient A.C., too, showed an only marginally increased response 
to OspA compared to medium. Though these effects could result from 
epitope-specific T cell suppression (see below), these experiments also need to 
be repeated.) 
In this small sample, then, T cell responsiveness to OspA correlated 
reasonably well with both disease activity and OspA seropositivity. If the 
former correlation persists after studying more patients, one might suppose 
that the responsive T cells are of the T helper type 1-like subset and may be 
contributing to disease activity and possibly inhibiting antibody production 
(model #2). However, if T cell responsiveness to OspA ultimately correlates 
better with OspA seropositivity, then one may speculate that the T helper type 
2-like subset is the predominant responder and that late seroconversion 
results from spirochetal factors (model #1). This model could explain 
occasional cases of T cell responsiveness in the absence of seropositivity (e.g., 
patient J.B.) as the result of lagging B cell responses to T cell help. Both cell 
types, of course, could be involved simultaneously. And which model is 
operative may differ among patients, depending possibly on their T cell 
profiles or other immune system factors. In order to clarify these possible 
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correlations, we plan to characterize T cell subsets explicitly in future human 
experiments using monoclonal antibody to cell surface markers. 
Interestingly, patient A.G. with early active disease showed decreased 
responsiveness to PHA when compared to the control subject and to patients 
with inactive disease. Though one can make no conclusions without 
measuring PHA responsiveness among the other patients with active disease, 
this finding is generally consistent with the report of Moffat et al. which 
documented increased suppressor cell activity and decreased responsiveness 
to PHA in early Lyme disease.15 Studying more patients would clarify this 
relationship. 
When T cell stimulation was seen, responses to recombinant OspA or 
whole-digest were lower than responses to the individual stimulatory 
fractions in two cases (patients A.C. and J.B.). This finding may have been 
due simply to higher antigen concentrations in the fractions. (The 
concentrations were not measured in these assays.) Alternately, this effect 
may have resulted from epitope-specific T cell suppression, in which the 
effects of suppressive epitopes in a system outweigh those of stimulatory 
epitopes contained on other antigens in the system or even within other 
regions of the same protein.48 In the current experiments, full-length OspA 
and whole cathepsin digests possibly contained such a range of counter- 
regulatory epitopes, causing a net decrease in T cell proliferation. Certain 
fractions happened to be enriched for stimulatory epitopes, leading to greater 
proliferation in patients with these epitope specificities. Identifying these 
stimulatory epitopes is of course crucial for designing the maximally effective 
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vaccine. Accordingly, this lab is now seeking to isolate the individual 
fragments which make up the stimulatory fractions. 
Also of ongoing interest is the problem of generalizability of these in 
vitro results to the in vivo setting. Although the posited role of cathepsin D 
in processing antigens for presentation with major histocompability complex 
(MHC) proteins was the rationale for using this enzyme in the current 
experiments, recent data suggests that APCs must be present for cathepsin D 
to process antigen into physiologically relevant peptides.57 Class II MHC 
proteins on APCs may serve to bind epitopes prior to digestion of overlapping 
ends by cathepsin D. Digestion of antigen in their absence may yield non- 
physiologic peptide fragments. Future experiments which include APCs in 
the cathepsin D digestion will clarify their role in this early phase of antigen 
presentation. 
Future Directions 
The goals of the present study—to identify OspA epitopes which 
stimulate T helper cells to promote antibody production, and to elucidate the 
temporal properties of OspA-specific T cell responses during the course of 
natural infection—are related. Future research will focus on further 
integrating these two perspectives, correlating the clinical, microbiologic, and 
serologic features of Lyme disease with T cell subtype responses to OspA 
epitopes. For example, how does the repertoire of OspA-specific T cells 
evolve during the course of infection, and is there a correlation between 
epitopes recognized and disease severity? Does the activity of T cell subtypes 
vary through disease, with T helper 1-like responses dominating during 
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active disease, and T helper 2-like responses appearing only later with OspA 
seroconversion? Answering these questions may provide pathogenetic and 
clinical insights. Thinking in terms of pathogenesis, for example, we might 
find that late OspA seroconversion and late disease exacerbations correspond 
to the delayed emergence of Borrelia burgdorferi from immunoprivileged 
sites, with simultaneous activation of T helper 1 and 2 subtypes. Thinking 
clinically, we might find that early T cell responses to OspA in the absence of 
measurable antibody titers predict worse outcomes—i.e., those patients who go 
on to develop secondary and tertiary disease manifestations despite 
"adequate" therapy. And patients with certain T cell response profiles may 
benefit from different treatment regimens than other patients. Though 
rooted in the search for a vaccine, these findings would have more general 
value in improving the understanding and management of Lyme disease. 

T Cell Responses to OspA 32 
ACKNOWLEDGEMENTS 
Linda Bockenstedt bravely agreed to advise me for this research project 
in full knowledge that I had never done scientific, much less bench, research. 
During the ensuing months, as I have (sometimes painfully) learned 
numerous research techniques and concepts for the first time, she has been a 
patient and kind teacher. I appreciate her help tremendously. 
I give many thanks also to the other faculty and staff who make up the 
Section of Rheumatology here at Yale. They welcomed me from the very 
beginning and have remained important sources of knowledge and support. 
I would like to acknowledge specifically the people who provided me 
with important reagents or performed assays, without whom I could not 
have completed this project. Linda Bockenstedt provided T cell hybridomas, 
recombinant OspA, and glutathione S-transferase, and tested one of the 
patients; Erol Fikrig provided recombinant GST-OspA fusion proteins; Kathy 
Deponte and Nancy Marcantonio provided CTLL-2 cells and cathepsin D- 
digested OspA fragments and tested two of the patients; and Stella Cretella 
performed serologic assays. 

T Cell Responses to OspA 33 
LITERATURE CITED 
1 Steere AC. “Lyme disease". New England Journal of Medicine 321: 586. 
1989. 
2 Steere AC, SE Malawista, JH Newman, PN Spieler, and NH Bartenhagen. 
"Antibiotic therapy in Lyme disease". Annals of Internal Medicine 93: 
108. 1980. 
3 Steere AC, GJ Hutchinson, DW Rahn, LH Sigal, JE Craft, ET DeSanna, and 
SE Malawista. "Treatment of the early manifestations of Lyme disease". 
Annals of Internal Medicine 99: 22. 1983. 
4 Steere AC, A Pachner, and SE Malawista. "Successful treatment of 
neurologic abnormalities of Lyme disease with high-dose intravenous 
penicillin". Annals of Internal Medicine 99: 767. 1983. 
5 Steere AC, J Green, RT Schoen, E Taylor, GJ Hutchinson, DW Rahn, and 
SE Malawista. "Successful parenteral penicillin therapy of established 
Lyme arthritis". New England Journal of Medicine 312: 869. 1985. 
6 Szczepanski A and JL Benach. "Lyme borreliosis: Host responses to 
Borrelia burgdorferiMicrobiological Reviews 55: 21. 1991. 
Simpson WJ et al. "Antibody to a 39-kD Borrelia burgdorferi antigen 
(P39) as a marker for infection in experimentally and naturally inoculated 
animals". Journal of Clinical Microbiology 29: 236. 1991. 
8 Craft JE, DK Fischer, GT Shimamoto, and AC Steere. "Antigens of 
Borrelia burgdorferi recognized during Lyme disease". Journal of Clinical 
Investigation 78: 934. 1986. 
Volkman et al. "Characterization of an immunoreactive 93-kDa core 
protein of Borrelia burgdorferi with a human IgG monoclonal antibody". 
Journal of Immunology 146: 3177. 1991. 
10 Hansen K et al. "Immunochemical characterization of and isolation of 
the gene for a Borrelia burgdorferi immunodominant 60-kD antigen 
common to a wide range of bacteria". Infection and Immunity 56: 2047. 
1988. 
11 Lefebvre RB, GC Perng, and RC Johnson. "The 83-kDa antigen of Borrelia 
burgdorferi which stimulates IgM and IgG responses in infected hosts is 

T Cell Responses to OspA 34 
expressed by a chromosomal gene". Journal of Clinical Microbiology 28: 
1673. 1990. 
12 Fikrig E, E Huguenel, R Berland, D Rahn, J Hardin, and RA Flavell. 'The 
serologic diagnosis of Lyme disease using recombinant OspA, OspB, and 
flagellin". Journal of Infectious Disease 165: 1127. 1992. 
13 Shanafelt MC, J Anzola, C Soderberg, H Yssel, CW Turck, and G Peltz. 
"Epitopes on the outer surface protein A of Borrelia burgdorferi 
recognized by antibodies and T cells of patients with Lyme disease". The 
Journal of Immunology 148: 218. 1992. 
14 Hardin JA, AC Steere, and SE Malawista. "The pathogenesis of arthritis 
in Lyme disease: humoral immune responses and the role of intra- 
articular immune complexes". Yale Journal of Biology and Medicine 57: 
589. 1984. 
15 Moffat CM, LH Sigal, AC Steere, DH Freeman, and JM Dwyer. "Cellular 
immune findings in Lyme disease: Correlation with serum IgM and 
disease activity". American Journal of Medicine 77: 625. 1984. 
16 Golightly M, Thomas J, Volkman D, and Dattwyler RJ. "Modulation of 
natural killer cell activity by Borrelia burgdorferi". Annals of the New 
York Academy of Sciences 539: 103. 1988. 
17 Pachner AR, AC Steere, LH Sigal, and CJ Johnson. "Antigen-specific 
proliferation of CSF lymphocytes in Lyme disease". Neurology 35: 1642. 
1985. 
18 Sigal LH, AC Steere, DH Freeman, and JM Dwyer. "Proliferative 
responses of mononuclear cells in Lyme disease: Reactivity to Borrelia 
burgdorferi antigens is greater in joint fluid than in blood". Arthritis and 
Rheumatism 29: 761. 1986. 
19 Krause A, GR Burmester, A Rensing, C Schoerner, UE Schaible, MM 
Simon, P Herzer, MD Kramer, and R Wallich. "Cellular immune 
reactivity to recombinant OspA and flagellin from Borrelia burgdorferi in 
patients with Lyme borreliosis: Complexity of humoral and cellular 
immune responses". Journal of Clinical Investigation 90: 1077. 1992. 
Dattwyler RJ, DJ Volkman, BJ Luft, JJ Halperin, J Thomas, and MG 
Golightly. "Seronegative Lyme disease: dissociation of specific T and B 
lymphocyte responses to Borrelia burgdorferi". New England Journal of 
Medicine 319: 1441. 1988. 
20 

T Cell Responses to OspA 35 
21 Zoschke DC, AA Skemp, and DL Defosse. "Lymphoproliferative 
responses to Borrelia burgdorferi in Lyme disease". Annals of Internal 
Medicine 114: 285. 1991. 
22 Yssel H, T Nakamoto, P Scneider, V Freitas, C Collins, D Webb, N Mensi, 
C Soderberg, and G Peltz. "Analysis of T lymphocytes cloned from the 
synovial fluid and blood of a patient with Lyme arthritis". International 
Immunology 2: 1081. 1990. 
23 Yssel H, MD Shanafelt, C Sodenberg, R Schneider, and G Peltz. "Borrelia 
burgdorferi activates a T helper type 1-like subset in Lyme arthritis". 
Journal of Experimental Medicine 174: 593. 1991. 
24 Shanafelt MC, Hindersson P, Soderberg C, Mensi N, Turck CW, Webb D, 
Yssel H, and Peltz G. "T cell and antibody reactivity with the Borrelia 
burgdorferi 60-kDa heat shock protein in Lyme arthritis". Journal of 
Immunology 146: 3985. 1991. 
25 Barthold SW et al. "Lyme borreliosis in selected strains of laboratory 
mice". Journal of Infectious Disease 162: 133. 1990. 
26 Barthold SW. "Infectivity of Borrelia burgdorferi relative to route of 
inoculation and genotype in laboratory mice". Journal of Infectious 
Disease 163: 419. 1991. 
27 Barthold SW, DH Persing, AL Armstrong, and RA Peeples. "Kinetics of 
Borrelia burgdorferi dissemination and evolution of disease following 
intradermal inoculation of mice". American Journal of Pathology 139: 
263: 1991. 
28 Barthold S. Personal communication. 
29 Schaible UE, MD Kramer, CWE Justus, C Museteanu, and MM Simon. 
"Demonstration of antigen-specific T cells and histopathological 
alterations in mice experimentally inoculated with Borrelia burgdorferi". 
Infection and Immunity 57: 41. 1989. 
30 deSouza MD, E Fikrig, AL Smith, RA Flavell, and SW Barthold. 
"Nonspecific proliferative responses of murine lymphocytes to Borrelia 
burgdorferi antigens". Journal of Infectious Disease 165: 471. 1992. 
31 Kochi SK and RC Johnson. "Role of IgG in killing of Borrelia burgdorferi 
by the classical complement pathway". Infection and Immunity 56: 314. 
1988. 

T Cell Responses to OspA 36 
32 Johnson RC, C Kodner, and M Russell. "Passive immunization of 
hamsters against experimental infection with the Lyme disease 
spirochete". Infection and Immunity 53: 713. 1986. 
33 Schaible UE et al. "The scid mouse: a laboratory model of Lyme arthritis 
and carditis". Journal of Experimental Medicine 170: 1427. 1989. 
34 Schaible UE et al. "Monoclonal antibodies specific for the outer surface 
protein A of Borrelia burgdorferi prevent Lyme borreliosis in scid mice". 
Proceedings of the National Academy of Science USA 87: 3768. 1990. 
35 Simon MM, UE Schaible, MD Kramer, C Eckerskorn, C Museteanu, HK 
Muller-Hermelink, and R Wallich. "Recombinant OspA from Borrelia 
burgdorferi induces antibodies protective against spirochetal infection of 
mice". Journal of Infectious Disease 164: 123. 1991. 
36 Fikrig E, SW Barthold, N Marcantonio, K Deponte, FS Kantor, and RA 
Flavell. "Roles of OspA, OspB, and flagellin in protective immunity to 
Lyme borreliosis in the laboratory mouse". Infection and Immunity 60: 
657. 1992. 
37 Fikrig E, SW Barthold, F Kantor, and RA Flavell. "Protection of mice 
against the Lyme disease agent by immunizing with recombinant OspA". 
Science 250: 553. 1990. 
38 Sears J, E Fikrig, T Nakagawa, K Deponte, N Marcantonio, F Kantor, and 
RA Flavell. "Molecular mapping of OspA-mediated protection against 
Borrelia burgdorferi, the Lyme disease agent". Journal of Immunology 
147: 1995. 1991. 
39 Fikrig E and RA Flavell. Submitted. 
40 Barbour AG and MF Schrumpf. "Polymorphism of major surface 
proteins of Borrelia burgdorferi". Zentralbl Bakteriol Mikrobiol Hyg A 
263: 83. 1986. 
41 Barbour AG, RA Heiland, and TR Howe. "Heterogeneity of major 
proteins in Lyme disease Borrelia: A molecular analysis of North 
American and European isolates". Journal of Infectious Disease 152: 478. 
1985. 
42 Fikrig E, SW Barthold, DH Persing, X Sen, FS Kantor, and RA Flavell. 
"Borrelia burgdorferi strain 25015: Characterization of OspA and 
vaccination against infection". Journal of Immunology 148: 2256. 1992 

T Cell Responses to OspA 37 
43 Cofman RL, B Seymour, D Lebman, D Hiraki, J Christianson, B Sharader, 
H Cherwinski, J Savelkoul, F Finkelman, M Bond, and TR Mosmann. 
"The role of helper T cell products in mouse B cell differentiation and 
isotype regulation". Immunology Review 102: 5. 1988. 
44 Allen JE et al. "A single peptide from the major outer membrane protein 
of Chlamydia trachomatis elicits T cell help for the production of 
antibodies to protective determinants". Journal of Immunology 147: 674. 
1991. 
45 Etlinger HM, D Gillessen, H-W Lahm, H Matile, H-J Schonfeld, A 
Trzeciak. "Use of prior vaccinations for the development of new 
vaccines". Science 249: 423. 1990. 
46 Kumar A, R Arora, P Kaur, VS Chauhan, and P Sharma. '"Universal' T 
helper cell determinants enhance immunogenicity of a Plasmodium 
falciparum merozoite surface antigen peptide". Journal of Immunology 
148: 1499. 1992. 
47 Milich DR, A McLachlan, GB Thornton, and JL Flughes. "Antibody 
production to the nucleocapsid and envelope of the hepatitis B virus 
primed by a single synthetic T cell site". Nature 329: 547. 1987. 
48 Adorini L, MA Flarvey, A Miller, and EE Sercarz. "Fine specificity of 
regulatory T cells. II. Suppressor and helper T cells are induced by 
different regions of hen egg lysozyme in a genetically non-responder 
mouse strain". Journal of Experimental Medicine 150: 293. 1979. 
49 Dunn JJ, BN Lade, and AG Barbour. "Outer surface protein A (OspA) 
from the Lyme disease spirochete, Borrelia burgdorferi: Fligh level 
expression and purification of a soluble recombinant form of OspA". 
Protein Expression & Purification 1: 159. 1990. 
50 “Production of mouse T cell hybridomas". Current Protocols in 
Immunology (ed. John E. Coligan et al.), unit 3.14. New York: Greene 
Publishing Associates and Wiley-Interscience, 1991. 
Kappler JW, B Skidmore, J White, and P Marrack. "Antigen-inducible H- 
2 restricted, interleukin-2-producing T cell hybridomas. Lack of 
independent antigen and H-2 recognition". Journal of Experimental 
Medicine 153: 1198. 1981. 
51 

T Cell Responses to OspA 38 
52 "Measurement of human and murine interleukin 2 and interleukin 4". 
Current Protocols in Immunology (ed. John E. Coligan et al.), unit 6.3. 
New York: Greene Publishing Associates and Wiley-Interscience, 1991. 
53 Gillis S, MM Ferm, W Ou, and KA Smith. "T cell growth factor: 
Parameters of production and a quantitative microassay for activity". 
Journal of Immunology 120: 2027. 1978. 
54 “T cell enrichment by nonadherence to nylon". Current Protocols in 
Immunology (ed. John E. Coligan et al.), unit 3.2. New York: Greene 
Publishing Associates and Wiley-Interscience, 1991. 
55 Julius MH, E Simpson, and LA Herzenberg. "A rapid method for the 
isolation of functional thymus-derived murine lymphocytes". European 
Journal of Immunology 3: 645. 1973. 
56 Van Noort JM and AC van der Drift. "Selectivity of cathepsin D suggests 
an involvement of the enzyme in the generation of T cell epitopes". 
Journal of Biological Chemistry 264: 14159. 1989. 
57 Delovitch TL and Y Lang. "MHC II may function as a template for the 
processing of a partially processed peptide into a T cell epitope". Journal 
of Cellular Biochemistry Supplement 17C: 67. 1993. 

T Cell Responses to OspA 39 
FIGURE LEGENDS 
Figures are attached. Legends for each figure are listed below. Positive 
and negative CTLL-2 controls were performed for each assay described in 
Figures 3 through 8, and they were normal, except as noted. Positive control 
was rIL-2 (50 pi, 1.3 U/ml starting concentration); negative control was assay 
medium. Ordinate axes were scaled equally for experiments performed under 
similar conditions. 
Figure 1 
Recombinant OspA and GST-OspA fragments. Numbers refer to the 
amino acid residues of full-length OspA. 
Table 1 
Clinical and serologic characterization of human Lyme disease patients. 
Serologic data are expressed as most dilute titers which resulted in a positive 
ELISA for Borrelia burgdorferi antigens—i.e., larger numbers to the right of 
the colon indicate higher antibody levels. N/A = not applicable or not 
available, EM = erythema migrans, Antibx = antibiotics. 
Figure 2 
Proliferative responses of CTLL-2 cells to various stimuli, measured as 
3H-thymidine incorporation and quantified as counts per minute (cpm). 
CTLL-2s were incubated with antigen overnight, then pulsed with 3H- 
thymidine overnight. Stimuli included assay medium alone, rOspA (50 
pg/ml), and rIL-2 (various concentrations). 
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Figure 3 
Proliferative responses of CTLL-2 cells to the supernatants of various 
hybridoma cultures, measured as 3H-thymidine incorporation and quantified 
as counts per minute (cpm). Hybridomas (#1-#14, except #10) were cultured 
for two days with the indicated antigens in the company of APCs, and the 
supernatants were used to stimulate CTLL-2 cells. CTLL-2s were incubated 
with supernatants for two days, then pulsed with 3H-thymidine for four 
hours. Unrelated hybridomas were included as negative controls: 
Hybridoma A was prepared from a mouse immunized with ovalbumin, and 
hybridoma B was prepared from a mouse immunized with acetylcholine 
receptor. The APCs used in this assay were from C3H/HeJ mice previously 
immunized with rOspA. Antigens included assay medium alone, rGST (50 
pg/ml), and rOspA (50 pg/ml). 
Figure 4 
Proliferative responses of CTLL-2 cells to the supernatants of various 
hybridoma cultures, measured as 3H-thymidine incorporation and quantified 
as counts per minute (cpm). Hybridomas (#1-#14, except #5 and #6) were 
cultured with the indicated antigens in the company of APCs, and the 
supernatants were used to stimulate CTLL-2 cells. CTLL-2s were incubated 
with supernatants for one day, then pulsed with 3H-thymidine overnight. 
The APCs used in this assay were from naive C3H/HeJ mice and were not 
irradiated. Antigens included rGST (50 (ig/ml) and rOspA (50 pg/ml). 
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Figure 5 
Proliferative responses of CTLL-2 cells to the supernatants of various 
hybridoma cultures, measured as 3H-thymidine incorporation and quantified 
as counts per minute (cpm). Hybridomas #1 to #14 were cultured with the 
indicated antigens in the company of APCs, and the supernatants were used 
to stimulate CTLL-2 cells. CTLL-2s were incubated with supernatants for one 
day, then pulsed with 3H-thymidine overnight. An unrelated hybridoma was 
also included as a negative control: Hybridoma A was prepared from a 
mouse immunized with SmD, a common autoantigen in systemic lupus. 
The APCs used in this assay were from naive C3H/HeJ mice and were 
irradiated. Antigens included rGST (50 pg/ml) and rOspA (50 pg/ml). 
Figure 6 
Proliferative responses of CTLL-2 cells to the supernatants of various 
hybridoma cultures, measured as 3H-thymidine incorporation and quantified 
as counts per minute (cpm). Hybridomas #6, #10, #12, and #14 (two 
hybridomas previously positive, and two previously negative) were cultured 
with the indicated antigens in the company of APCs, and the supernatants 
were used to stimulate CTLL-2 cells. CTLL-2s were incubated with 
supernatants for two days, then pulsed with 3H-thymidine for four hours. A 
parallel experiment used APCs without any hybridoma (column 1) as a 
negative control. The APCs used in this assay were from naive C3H/HeJ 
mice and were irradiated. Antigens were newly made in this assay and 
included assay medium alone, rGST (50 |ig/ml), and rOspA (50 pg/ml). 
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The CTLL-2 assay controls failed in this experiment for unknown 
reasons (data not shown). It is possible that the positive and negative control 
antigens were mixed up. 
Figure 7 
Proliferative responses of CTLL-2 cells to the supernatants of various 
hybridoma cultures, measured as 3H-thymidine incorporation and quantified 
as counts per minute (cpm). Hybridomas #15 through #19 were cultured 
with the indicated antigens in the company of APCs (except as noted), and the 
supernatants were used to stimulate CTLL-2 cells. CTLL-2s were incubated 
with supernatants for two days, then pulsed with 3H-thymidine for four 
hours. The APCs used in this assay were from C3H/HeJ mice previously 
immunized with recombinant OspA and were irradiated. Antigens included 
assay medium alone, rGST (50 pg/ml), and rOspA (50 |ig/ml). 
Figure 8 
Proliferative responses of CTLL-2 cells to the supernatants of various 
hybridoma #12 cultures, measured as 3H-thymidine incorporation and 
quantified as counts per minute (cpm). Hybridoma #12 was cultured with the 
indicated antigens in the company of APCs (except as noted), and the 
supernatants were used to stimulate CTLL-2 cells. CTLL-2s were incubated 
with supernatants for two days, then pulsed with 3H-thymidine for four 
hours. The APCs used in this assay were from C3H/HeJ mice previously 
immunized with recombinant OspA and were irradiated. Antigens included 
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assay medium alone, rGST (10 pg/ml), rOspA (10 pg/ml), and the indicated 
rGST-OspA fragments (10 |ig/ml). 
Figure 9 
Proliferative responses of human nylon wool-purifed (NWP) T cells to 
various stimuli, measured as 3H-thymidine incorporation and quantified as 
counts per minute (cpm). T cells from healthy control D.D. were incubated 
for two days with the indicated antigens in the company of APCs, then pulsed 
with 3H-thymidine for four hours. Stimuli included assay medium alone 
(supplemented with autologous serum), PHA (1 pg/ml), whole digest of 
OspA by cathepsin D (concentration unknown), and various fractions (Fx) of 
the digest (concentrations unknown). 
Figure 10 
Proliferative responses of human nylon wool-purifed (NWP) T cells to 
various stimuli, measured as 3H-thymidine incorporation and quantified as 
counts per minute (cpm). T cells from patient N.R. were incubated for two 
days with the indicated antigens in the company of APCs, then pulsed with 
3H-thymidine for four hours. Stimuli included assay medium alone 
(supplemented with autologous serum or fetal calf serum), PHA (1 pg/ml), 
rOspA (50 |ig/ml), and various fractions (Fx) of the cathepsin D digest of OspA 
(concentrations unknown). 
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Figure 11 
Proliferative responses of human nylon wool-purifed (NWP) T cells to 
various stimuli, measured as 3H-thymidine incorporation and quantified as 
counts per minute (cpm). T cells from patient A.G. were incubated for two 
days with the indicated antigens in the company of APCs, then pulsed with 
3H-thymidine for four hours. Stimuli included assay medium alone 
(supplemented with fetal calf serum), PHA (1 pg/ml), rOspA (50 pg/ml), 
whole digest of OspA by cathepsin D (concentration unknown), and various 
fractions (Fx) of the digest (concentrations unknown). 
Figure 12 
Proliferative responses of human nylon wool-purifed (NWP) T cells to 
various stimuli, measured as 3H-thymidine incorporation and quantified as 
counts per minute (cpm). T cells from patient J.B. were incubated for two 
days with the indicated antigens in the company of APCs, then pulsed with 
3H-thymidine for four hours. Stimuli included assay medium alone 
(supplemented with fetal calf serum), rOspA (50 (ig/ml), whole digest of OspA 
by cathepsin D (concentration unknown), and various fractions (Fx) of the 
digest (concentrations unknown). 
Figure 13 
Proliferative responses of human nylon wool-purifed (NWP) T cells to 
various stimuli, measured as 3H-thymidine incorporation and quantified as 
counts per minute (cpm). T cells from patient S.A. were incubated for two 
days with the indicated antigens in the company of APCs, then pulsed with 
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3H-thymidine for four hours. Stimuli included assay medium alone 
(supplemented with autologous serum), PHA (1 gg/ml), whole digest of 
OspA by cathepsin D (concentration unknown), and various fractions (Fx) of 
the digest (concentrations unknown). 
Figure 14 
Proliferative responses of human nylon wool-purifed (NWP) T cells to 
various stimuli, measured as 3Fl-thymidine incorporation and quantified as 
counts per minute (cpm). T cells from patient A.C. were incubated for two 
days with the indicated antigens in the company of APCs, then pulsed with 
3Ff-thymidine for four hours. Stimuli included assay medium alone 
(supplemented with autologous serum), rOspA (50 pg/ml), whole digest of 
OspA by cathepsin D (concentration unknown), and various fractions (Fx) of 
the digest (concentrations unknown). 
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